Clinical Trials Logo

Plaque clinical trials

View clinical trials related to Plaque.

Filter by:

NCT ID: NCT03550651 Completed - Clinical trials for Periodontal Diseases

Evaluation of Antiplaque Efficacy of Licorice Extract Mouthrinse & HSS and Their Comparison With EO & CHX Mouthrinse

Start date: August 2016
Phase: N/A
Study type: Interventional

Periodontal disease is a multifactorial disease caused by mainly bacterial, genetic, immunological, and environmental factors. Chronic periodontitis, one of the widely prevalent forms of periodontal disease, is characterized by loss of attachment apparatus of the tooth; it can lead to tooth loss. Many non surgical and surgical approaches have been adapted time and again to prevent, intercept, and to treat the various forms of chronic periodontitis. But, these treatment modalities are not approachable by all individuals, because of the various factors such as: low socioeconomic status, illiteracy, high cost of the treatment, no availability of easy and uncomplicated treatment nearby etc. Considering these factors, there are still a need of preventive, practical, and affordable treatment options specially for the population of underdeveloped and developing countries.

NCT ID: NCT03421145 Completed - Plaque Clinical Trials

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

Start date: December 17, 2017
Phase:
Study type: Interventional

Rinse contains an anti-plaque agent that helps prevent the accumulation of dental plaque associated with gingivitis.

NCT ID: NCT03214406 Completed - Gingivitis Clinical Trials

Clinical Evaluation of the Efficacy of a Marketed Dentifrice on Plaque and Gingivitis

Start date: February 8, 2010
Phase: N/A
Study type: Interventional

Parallel, double blind, randomized, Institutional Review Board (IRB) -approved study involving approximately 160 subjects to complete. Subjects were randomly assigned to either the test product (Arm & Hammer Advance White Brilliant Sparkle) or the control (Crest Cavity Protection Regular) based on baseline mean whole-mouth plaque and gingival scores and age.Subjects brushed with their assigned dentifrice two times (2X) daily and were evaluated for gingivitis, bleeding and plaque at Baseline and after 4-, 8-, and 12-weeks of product use. Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.

NCT ID: NCT02980497 Completed - Gingivitis Clinical Trials

Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study

Start date: September 2013
Phase: N/A
Study type: Interventional

The objective of this randomized, single-center, examiner-blind, controlled, parallel group, six-month clinical study is to compare the antiplaque/antigingivitis potential of a no-alcohol essential oil containing mouthrinse and an alcohol essential oil containing mouthrinse. A negative control group using only an ADA Accepted anticavity toothpaste will be included.

NCT ID: NCT02666508 Completed - Inflammation Clinical Trials

Trial of Toothpaste to Reduce Plaque and Inflammation

Start date: September 1, 2015
Phase: N/A
Study type: Interventional

Dental plaque causes caries and periodontal disease and data are sparse about toothpaste and plaque removal. Inflammation, caused by dental plaque, is a risk factor for cardiovascular disease. (CVD) The availability of (Plaque HD (TM), a plaque identifying toothpaste with targetol technology (TM)), afforded the unique opportunity to test whether there were statistically significant and clinically important reductions in plaque and inflammation in a randomized trial of apparently healthy individuals.

NCT ID: NCT02635789 Completed - Plaque Clinical Trials

Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

Start date: December 2015
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)

NCT ID: NCT02634931 Completed - Plaque Clinical Trials

Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex

Start date: December 2015
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients with tuberous sclerosis complex in the open-label trial.

NCT ID: NCT02574221 Completed - Gingivitis Clinical Trials

A Pilot Study to Evaluate a Molecular Method for Plaque

Start date: August 2015
Phase: N/A
Study type: Interventional

This study is to evaluate the sensitivity of the molecular method and its ability to split a stannous fluoride toothpaste versus a negative control.

NCT ID: NCT02543060 Completed - Gingivitis Clinical Trials

A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular Dentifrice

Start date: June 2015
Phase: N/A
Study type: Interventional

This study will evaluate the sensitivity of an assay and its ability to split a marketed stannous fluoride toothpaste versus a negative control.

NCT ID: NCT02377310 Completed - Clinical trials for Coronary Artery Disease

Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography

VERIFY2
Start date: September 2013
Phase: N/A
Study type: Observational

Instantaneous wave-free ratio (iFR™) is a novel non-hyperaemic index of the functional significance of a coronary stenosis. Previous studies have shown variable levels of correlation with the established hyperaemic index FFR. In addition it has been proposed that iFR™ has superior diagnostic accuracy when compared to mean whole cardiac cycle Pd/Pa which can also be used to predict FFR. We plan to undertake a prospective clinical study in consecutive patients already undergoing FFR assessment in the cardiac catheterisation laboratory to compare the ability of iFR™ and Pd/Pa (both measured using the proprietary Volcano system) to predict FFR. We will explore the level of misclassification of flow limiting disease that results from use of iFR™ and resting Pd/Pa employed using either binary cut-off algorithms or in a hybrid decision making protocol. We plan to analyse 260 vessels over a 18 month period. Hyperaemia will be induced by intravenous adenosine (140 ug/kg/min) administered wherever possible via an antecubital vein. Intra-coronary nitrates will also be given in line with the standard care procedure for FFR measurement. Final clinical decisions following coronary physiology will be based on steady state FFR.